Antireflux versus conventional self-expanding metallic Stents (SEMS) for distal esophageal cancer: results of a multicenter randomized trial
Emmanuel Coron(Centre Hospitalier Universitaire de Nantes), Bertrand Vedrenne(Centre Hospitalier de Mulhouse), Frédéric Prat(Hôpital Cochin), Thierry Barrioz(Centre Hospitalier Universitaire de Poitiers), Philippe Bichard, Marc Le Rhun, Dimitri Coumaros(Hôpital Civil, Strasbourg), C. Boustière(Hôpital Saint Joseph), Jérémy Brégeon(Inserm), Jérémie Jacques(Centre Hospitalier Universitaire de Limoges), Anne Le Sidaner(Aix-Marseille Université), Yann Touchefeu(Canadian Partnership Against Cancer), Christelle Volteau(Nantes Université), Giulia David(Centre Hospitalier Universitaire de Nantes), Stéphane Lecleire(Inserm)
Cited by 18
Related Papers
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|JAMA Oncology|2022|336
The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients With Differences According to the Disease Subtype
|The American Journal of Gastroenterology|2011|290
A neural network algorithm for detection of GI angiectasia during small-bowel capsule endoscopy
|Gastrointestinal Endoscopy|2018|208
Baseline Nutritional Status Is Predictive of Response to Treatment and Survival in Patients Treated by Definitive Chemoradiotherapy for a Locally Advanced Esophageal Cancer
|The American Journal of Gastroenterology|2007|183
Increased Proteasome-Mediated Degradation of Occludin in Irritable Bowel Syndrome
|The American Journal of Gastroenterology|2009|182